Registered No: 03861669

THE COMPANIES ACT 1985

RESOLUTIONS

of

BIOWISDOM LIMITED (the "Company")

AT AN EXTRAORDINARY GENERAL MEETING of the Company duly convened and held on 4 May 2007, the following resolutions were passed in the case of resolution 1, as an extraordinary resolution and in the case of resolution 2, as a special resolution

EXTRAORDINARY RESOLUTION

THAT in accordance with article 10 of the Company's articles of association (the 'Articles') and section 95 of the Companies Act 1985, the rights of pre-emption set out at article 10 of the Articles any other provision of the Articles or otherwise shall not apply to the issue by the Company on or about the date hereof of convertible loan notes nor to the allotment at any time of any shares in the capital of the Company (of whatsoever class including preferred ordinary shares of £0 01 each) in accordance with the terms of such convertible loan notes, provided that the principal amount of such convertible loan notes shall not exceed £2 083 530 in aggregate nominal amount

SPECIAL RESOLUTION

THAT the Company's articles of association (the Articles") be amended in respect of Article 3 by deletion of the existing definition of "Listing" and replacement thereof with the following definition

"Listing" means the admission of all or any of the Company's shares to the Official List of the UK Listing Authority or the admission of the same to trading on the AlM Market of the London Stock Exchange plc or the admission of the same to or the grant of permission by any like authority for the same to be traded on, any Recognised Investment Exchange or other equivalent or similar share market

Duted ATH MAY . 2007

Chairman

WEDNESDAY



CERTIFIED TO BE A TRUE AND

*1cKcnna

C M. 16L

Long

Y OF THE ORIG

L14

31/10/2007 COMPANIES HOUSE 300

Registered Number: 03861669

THE COMPANIES ACT 1985

CERTIFIED TO BE A TRUE AND COMPLETE COPY OF THE ORIGINAL PROPERTY OR THE ORIGINAL PROPERTY OF THE ORIGINAL PROPERTY OF TH

CMS Cameron McKenna Mitre House 160 Aldersgate Simon

London EC 14 36

WRITTEN RESOLUTION

of

BIOWISDOM LIMITED (the "Company")

Dated 19 DECEMBER 2006

We, the undersigned, being all the members of the Company who would, at the date of this resolution, have been entitled to attend and vote upon them if it had been proposed at a general meeting at which we were present RESOLVE in writing as follows, such resolution to have effect as an extraordinary resolution in accordance with the Company's articles of association:

EXTRAORDINARY RESOLUTION

THAT in accordance with article 10 of the Company's articles of association (the "Articles") and section 95(1) of the Companies Act 1985, the rights of pre-emption set out at article 10 of the Articles, any other provision of the Articles or otherwise shall not apply to the allotment of any shares in the capital of the Company (of whatsoever class including preferred ordinary shares of £0.01 each) which are proposed to be allotted in connection with the acquisition (howsoever structured) by the Company of shares in, and/or the business of, Omniviz, Inc in accordance with a share purchase agreement to be entered into between the Company and Battelle Memorial Institute and/or any other documentation entered into in connection therewith

Adnan Capnotti	Andrew Richards
Arthur Thomas	Barry Price
Derek Jones	Gordon Smith Baxter

Registered Number: 03861669

THE COMPANIES ACT 1985

WRITTEN RESOLUTION

٥f

BIOWISDOM LIMITED (the "Company")

Dated

2006

We, the undersigned, being all the members of the Company who would, at the date of this resolution, have been entitled to attend and vote upon them if it had been proposed at a general meeting at which we were present RESOLVE in writing as follows, such resolution to have effect as an extraordinary resolution in accordance with the Company's articles of association.

EXTRAORDINARY RESOLUTION

THAT in accordance with article 10 of the Company's articles of association (the "Articles") and section 95(1) of the Companies Act 1985, the rights of pre-emption set out at article 10 of the Articles, any other provision of the Articles or otherwise shall not apply to the allotment of any shares in the capital of the Company (of whatsoever class including preferred ordinary shares of £001 each) which are proposed to be allotted in connection with the acquisition (howsoever structured) by the Company of shares in, and/or the business of, Omniviz, Inc in accordance with a share purchase agreement to be entered into between the Company and Battelle Memorial Institute and/or any other documentation entered into in connection therewith.

Adrian Capriotti	Andrew Richards
Arthur Thomas	Barry Price
 Derek Jones	Gordon Smuth Baxter

THE COMPANIES ACT 1985

WRITTEN RESOLUTION

of

BIOWISDOM LIMITED (the "Company")

Dated

2006

We, the undersigned, being all the members of the Company who would, at the date of this resolution, have been critical to attend and vote upon them if it had been proposed at a general meeting at which we were present RESOLVE in writing as follows, such resolution to have effect as an extraordinary resolution in accordance with the Company's articles of association

EXTRAORDINARY RESOLUTION

IFIAT in accordance with article 10 of the Company's articles of association (the "Articles") and section 95(1) of the Companies Act 1985, the rights of pre-emption set out at article 10 of the Articles, any other provision of the Articles or otherwise shall not apply to the allotment of any shares in the capital of the Company (of whatsoever class including preferred ordinary shares of £0.01 each) which are proposed to be allotted in connection with the acquisition (howsoever structured) by the Company of shares in, and/or the business of, Omny 12, Inc in accordance with a share purchase agreement to be entered into between the Company and Battelle Memorial Institute and/or any other documentation entered into in connection therewith

Adrian Capriotti

Andrew Richards

Arthur Thomas

Barry Price

Dor Lloges

Gordon Smith Baxter

Registered Number 03861669

THE COMPANIES ACT 1985

WRITTEN RESOLUTION

of

BIOWISDOM LIMITED (the "Company")

Dated

2006

We, the undersigned, being all the members of the Company who would, at the date of this resolution, have been entitled to attend and vote upon them if it had been proposed at a general meeting at which we were present RESOI VF in writing as follows such resolution to have effect as an extraordinary resolution in accordance with the Company's articles of association:

EXTRAORDINARY RESOLUTION

THAT in accordance with article 10 of the Company's articles of association (the "Articles") and section 95(1) of the Companies Act 1985, the rights of pie-emption set out at article 10 of the Articles, any other provision of the Articles or otherwise shall not apply to the allotment of any shares in the capital of the Company (of whatsoever class including preferred ordinary shares of £0.01 each) which are proposed to be allotted in connection with the acquisition (howsoever structured) by the Company of shares in, and/or the business of, Omniviz, Inc in accordance with a share purchase agreement to be entered into between the Company and Battelle Memorial Insurite and/or any other documentation entered into in connection therewith.

Adrian Capriotu	Andrew Richards
Arthur Thomas	Barry Price
Durck Jones	Gordon Smith Baxter

Registered Number 03861669

THE COMPANIES ACT 1985

WRITTEN RESOLUTION

of

BIOWISDOM LIMITED (the "Company")

Dated

2006

We, the undersigned, being all the members of the Company who would, at the date of this resolution, have been entitled to attend and vote upon them if it had been proposed at a general meeting at which we were present RESOLVE in writing as follows, such resolution to have effect as an extraordinary resolution in accordance with the Company's articles of association:

EXTRAORDINARY RESOLUTION

THAT in accordance with article 10 of the Company's articles of association (the "Articles") and section 95(1) of the Companies Act 1985, the rights of pre-emption set out at article 10 of the Articles, any other provision of the Articles or otherwise shall not apply to the allotment of any shares in the capital of the Company (of whatsoever class including preferred ordinary shares of £0.01 each) which are proposed to be allotted in connection with the acquisition (howsoever structured) by the Company of shares in, and/or the business of, Omniviz, Inc in accordance with a share purchase agreement to be entered into between the Company and Battelle Memonal Institute and/or any other documentation entered into in connection therewith.

Adrian Capriotti	Andrew Richards
Arthur Thomas	Barry Price
Derek Jones	Gordon Smith Baxter

THE COMPANIES ACT 1985

WRITTEN RESOLUTION

of

BIOWISDOM LIMITED (the "Company")

Dated

2006

We, the undersigned, being all the members of the Company who would, at the date of this resolution, have been childed to attend and vote upon them if it had been proposed at a general meeting at which we were present RESOLVE in writing as follows, such resolution to have effect as an extraordinary resolution in accordance with the Company's articles of association.

EXTRAORDINARY RESOLUTION

THAT in accordance with article 10 of the Company's articles of association (the "Articles") and section 95(1) of the Companies Act 1985, the rights of pre-emption set out at article 10 of the Articles, any other provision of the Articles or otherwise shall not apply to the allotment of any shares in the capital of the Company (of whatsoever class including preferred ordinary shares of £0.01 each) which are proposed to be allotted in connection with the acquisition (howsoever structured) by the Company of shares in, and/or the business of, Omniviz, Inc in accordance with a share purchase agreement to be entered into between the Company and Battelle Memorial Institute and/or any other documentation entered into in connection therewith.

A SIN

Adman Capriotti	Andrew Bachards
Arthur Thomas	Barry Price
Derek Jones	Gordon Smith Baxter

k o idle

Kenneth Pelton

Robert Pettigrew

Tom Flanigan

The Generics Group AG

Julie Barnes

Susan Lowther

Trustees of the MB Venture Capital Fund 1 N.V.

Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG

Merlin General Partner III Ltd as General Partner of Merlin BioSciences Fund III LP The Bank of New York (Nominces) Ltd

NIF Ventures Co Ltd

Venture Capital Investment Ltd Partnership NIF Global

Venture Capital Investment 1 td Partnership NIF Japan – USA – Europe Bridge Fund

Presented by.
CMS Cameron McKenna LLP
Mitre House
160 Aldersgate Street
London ECLA 4DD
Ref ZEM/120642.00006

Kenneth Pelton	Robert Pertigrew
Two P. R. Tom Flanigan	The Generics Group AG
Julie Barnes	Susan Lowther
Trustees of the MB Venture Capital Fund 1 N V	Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG
Merlin General Partner III Ltd as General Partner of Merlin BioSciences Fund III LP	The Bank of New York (Nominees) Ltd
NIF Ventures Co Ltd	Venture Capital Investment Ltd Partnership NII ⁷ Global
Venture Capital Investment Ltd Partnership NIF Japan – USA – Europe Bridge Fund	
Presented by: CMS Cameron McKenna LLP	

Mitre House

160 Aldersgate Street London EC1A 4DD

Ref ZEM/120642 00006

Kenneth Pelton	Robert Pettigrew
Tom Flanigan	The Genencs Group AG
Julie Barnes	Swan Lowther
Alison Lloyd	Tracy Willmott
Michelle Maxwell	
Trustees of the MB Venture Capital Fund 1 N.V	Merhn Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG
Merlin General Partner III Ltd as General Partner of Merlin BioSciences Fund III LP	The Bank of New York (Nominees) Ltd
NIF Ventures Co Ltd	Venture Capital Investment Ltd Partnership NIF Global
Venture Capital Investment Ltd Partnership NIF Japan – USA – Europe Bridge Fund	
Presented by CMS Cameron McKenna LLP Mitre House 160 Aldersgate Street London EC1A 4DD Ref ZEM/120642.00006	

(21950003.01)

Kunneth Pelton

Robert Petngrew

Tom Flangan

The Genenes Group AG

Julie Batrics

Susan Lowther

Alison Hoyd

Tracy Willmort

Michelle Maxwell

Trustees of the MB Venture Capital Fund 1 NV

Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences I und III GmbH & Co KG

Merlin General Partner III Ltd as General Partner of Merlin BioSciences Lund III LP The Bank of New York (Nominees) Ltd

NIF Ventures Co Ltd

Venture Capital Investment Ltd Partnership NIF Global

Venture Capital Investment Ltd Partnership NI: Japan – USA – Europe Bridge Fund

Presented by CMS Cameron McKenna LLP Mitre House 160 Aldersgate Street London EC1A 4DD Ref. ZEM/120642 00006 2193003301)

Kenneth Pelton	Robert Pettigrew
Tom Flanigan	The Generics Group AG
Julic Barnes	Susan Lowther
Alison Lloyd	Tracy Willmott
Michelle Maxwell	
Trustees of the MB Venture Capital Fund 1 N.V.	Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG
Merlin General Partner III Ltd as General Partner of Merlin BioSciences Fund III LP	The Bank of New York (Nomunees) Ltd
NIF Ventures Co Ltd	Venture Capital Investment Ltd Partnership NIF Global
Venture Capital Investment Ltd Partnership NIF Japan – USA – Europe Bridge Fund	
Presented by: CMS Cameron McKenna LLP Mitre House 160 Aldersgate Street London EC1A 4DD Ref: ZEM/120642.00006	

(21950003 01)

Kenneth Pelton	Robert Petngrew
Fom Flangan	The Generics Group 1G)
Julie Barnes	Susan Lowther
Trustees of the MB Venture Capital Fund 1 N V	Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG
Merlin General Partner III Ltd as General Partner of Merlin BioSciences Fund III LP	The Bank of New York (Nominees) Ltd
NIF Ventures Co Ltd	Venture Capital Investment Ltd Partnership NIF Global
Venture Capital Investment Ltd Partnership NIF Japan – US \ – Europe Bridge I und	
Presented by: CMS Cameron McKenna LLP Mitre House	

(21950003 01)

160 Aldersgate Street London EC1A 4DD Ref. ZEM/120642.00006 Kenneth Pelton

Robert Pettigrew

Tom Flanigan

The Generics Group AG

Julie Barnes

S& Lauther

Alison Lloyd

Tracy Willmott

Michelle Maxwell

Trustees of the MB Venture Capital I and 1 N V

Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences I und III GmbH & Co KG

Merlin General Partner III Ltd as General Partner of Merlin BioSciences Fund III LP The Bank of New York (Nominces) Ltd

NIF Ventures Co Ltd

Venture Capital Investment Ltd Partnership NIF Global

Venture Capital Investment I td Partnership NII: Japan – USA – Europe Bridge Fund

Presented by CMS Cameron McKenna LLP Mitre House 160 Aldersgate Street London EC1 V 4DD Ref ZEM/120642 00006 (21950003 01)

Kenneth Pelton	Robert Pettigrew
Tom Flanigan	The Generics Group AG
le Barnes	Susan Lowther
MB Venture Capital Fund 1.V.V	Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG
Meilin General Partner III Ltd as General Partner of Merlin BioSciences Pund III LP	The Bank of New York (Nominees) Ltd
NIF Ventures Co Ltd	Venture Capital Investment Ltd Partnership NIF Global
Venture Capital Investment Ltd Partnership NIF Japan – USA – Europe Bridge Fund	
Presented by: CMS Cameron McKenna LLP Mitte House 160 Aldersgate Street London EC1A 4DD Ref: ZEM/120642 00006	

Kenneth Pelton	Robert Petugrew
Tom Flanigan	The Generics Group AG
Julic Barnes	Susan Lowther
Trustees of the MB Venture Capital Γund 1 N.V.	Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG
Merlin General Partner III Ltd as General Partner of Morlin BioSciences Fund III LP	The Bank of New York (Nommees) Ltd
NIF Ventures Co Ltd	Venture Capital Investment Ltd Partnership NIF Global
Venture Capital Investment Ltd Partnership NII' Japan – USA – Europe Bridge Fund	
Presented by CMS Cameron McKenna LLP Mitre House 160 Aldersgate Street London ECIA 4DD Ref ZEM/120642.00006	

Kenneth Pelton

Robert Pettigrew

Tom I-lanigan

The Generics Group AG

Julie Barnes

Susan Lowther

Trustees of the MB Venture Capital Fund 1 $N\,V$

Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG

DENZIL BOSCHAT

DRECTOR

Merlin General Partner III Ltd as General Partner of Merlin BioSciences Fund III LP The Bank of New York (Nominces) Ltd

NIF Ventures Co Ltd

Venture Capital Investment Ltd Partnership NIF Global

Venture Capital Investment Ltd Partnership NIF Japan – USA – Europe Bridge Fund

Presented by CMS Cameron McKenna LLP Mitre House 160 Aldersgate Street London EC1A 4DD Ref ZEM/120642 00006

Kenneth Polton	Robert Pertigrew
Tom Flanigan	The Generics Group AG
Juhe Barnes	Susan Lowther
	V. Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG
Merlin General Partner III Ltd as General Partner of Merlin BioSciences Fund III LP MIF SMBC Ventures Co Ltd Tamiaki Hio-Executive Officer Venture Capital Investment Ltd Partnership NIF Japan USA – Europe Bridge Fund Shinichiro Hakuta-General Manager	The Bank-of New York (Nominees) Ltd Venture Capital Investment Ltd Partnership NIF Global Fund Shinichiro Hakuta-General Manager
Presented by: CMS Cameron McKenna LLP Mitre House 160 Aldersgate Street London EC1A 4DD Ref: ZEM/120642.00006	

(21950003.01)

Kenneth Pelton Robert Petugrew Tom Flanigan The Generics Group AG Julie Barnes Susan Lowther Tracy Willmott Alison Lloyd Michelle Maxwell Trustees of the MB Venture Capital Fund 1 N V Merlin Biosciences General Partner III GmbH as managing partner of the Merlin BioSciences Fund III GmbH & Co KG Merlin General Partner III Ltd as General The Bank of New York (Nominees) Ltd. Partner of Merlin BioSciences Fund III LP

> Venture Capital Investment Ltd Partnership NIF Global

Venture Capital Investment Ltd Partnership NIF Japan – USA – Europe Bridge Fund

Presented by CMS Cameron McKenna LLP Mitre House 160 Aldersgate Street London EC1A 4DD Ref ZEM/120642 00006 (21950003 01)

NIF Ventures Co Ltd